Metanavigation:

Hier finden Sie den Zugang zur Notfallseite, Kontaktinformationen, Barrierefreiheits-Einstellungen, die Sprachwahl und die Suchfunktion.

Navigation öffnen

Sie befinden sich hier:

Research Focus

Our research is focusing on the inflammatory and immunological mechanisms of host-pathogen interactions in the human alveolar compartment. Using vital human lung tissue or adult-stem cell derieved lung organoids, we model aspects of pneumonia caused by key respiratory pathogens such as Streptococcus pneumoniae, influenza A virus (IAV), or corona viruses.

To dissect cellular communication - particularly between alveolar macrophages and alveolar epithelial and endothelial cells - we apply a broad range of molecular biology and biochemical techniques. A central pillar of our work is high-end fluorescence microscopy, which allows us to visualize infection dynamics in real time. Techniques include live-cell and -tissue imaging, Light Sheet microscopy, FLIM-FRET, FCS, FRAP, spectral imaging, linear unmixing, high-content slide scanning, and super-resolution microscopy.

Microenvironmental acidification by pneumococcal sugar consumption fosters barrier disruption and immune suppression in the human alveolus. AM: alveolar macrophage; ATI/II: alveolar type I/II cells; EC: endothelial cells; ZO: zonula occludens protein; VE: vascular endothelial; Strep. pneumoniae: Streptococcus pneumoniae; IL: interleukin; H+: hydrogen; GM-CSF: granulocyte–macrophage colony-stimulating factor; COX: cyclo-oxygenase. Fatykhova et al. ERJ 2024

Current research addresses the tropism and immune activation of e.g. highly pathogenic H5N1 IAV, the role of barrier dysfunction following pneumococcal infection (see illustration) or the in-depth characterization of epithelial organoid differentiation.

In parallel, we develop next-generation 3D human disease models. Our aim is twofold: to create reliable human-specific non-animal models, and to identify central disease mechanisms of pneumonia. Our research was awarded the first research prize for Animal Experimental Alternatives of the State of Berlin in 2011.

Past, current and future consortia/funding: EC3R  (Einstein Foundation), Charité 3R  (Charité), SFB-TR84 (DFG), NUM-Organo-Strat  (BMBF), RAPID  (BMBF), PROGRESS  (BMBF),  FLU-PREP (BMBF - starting 2026).

Andreas Hocke© Fächerverbund Infektiologie, Pneumologie und Intensivmedizin/Charité

You are interested in our work? Watch the short video clip developed as part of the Einstein Center 3R and get an insight into our laboratory.